Bruker (NASDAQ:BRKR) Given New $69.00 Price Target at Barclays

Bruker (NASDAQ:BRKR) had its price objective cut by Barclays from $75.00 to $69.00 in a report issued on Wednesday, Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

BRKR has been the subject of several other reports. TD Cowen dropped their price objective on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research report on Wednesday, August 7th. Wells Fargo & Company started coverage on shares of Bruker in a report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 target price for the company. The Goldman Sachs Group decreased their price target on shares of Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Finally, Citigroup cut their target price on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $79.36.

Bruker Price Performance

BRKR stock opened at $59.34 on Wednesday. The company’s 50-day moving average price is $63.97 and its two-hundred day moving average price is $66.51. The firm has a market cap of $8.98 billion, a P/E ratio of 24.47, a P/E/G ratio of 2.32 and a beta of 1.20. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. Bruker has a 12 month low of $54.55 and a 12 month high of $94.86.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 11.29% and a return on equity of 24.92%. The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same period last year, the business earned $0.74 earnings per share. The business’s revenue was up 16.4% compared to the same quarter last year. On average, analysts anticipate that Bruker will post 2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bruker

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mutual of America Capital Management LLC grew its stake in shares of Bruker by 7.1% in the third quarter. Mutual of America Capital Management LLC now owns 59,728 shares of the medical research company’s stock worth $4,125,000 after purchasing an additional 3,978 shares during the last quarter. Natixis Advisors LLC lifted its holdings in Bruker by 12.3% during the 3rd quarter. Natixis Advisors LLC now owns 146,694 shares of the medical research company’s stock worth $10,131,000 after buying an additional 16,044 shares during the period. Ferguson Wellman Capital Management Inc. grew its position in shares of Bruker by 16.5% in the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 16,041 shares of the medical research company’s stock valued at $1,108,000 after buying an additional 2,270 shares during the last quarter. KBC Group NV grew its position in shares of Bruker by 1.8% in the 3rd quarter. KBC Group NV now owns 42,680 shares of the medical research company’s stock valued at $2,947,000 after buying an additional 763 shares during the last quarter. Finally, Aptus Capital Advisors LLC increased its stake in shares of Bruker by 15.8% in the third quarter. Aptus Capital Advisors LLC now owns 40,522 shares of the medical research company’s stock valued at $2,798,000 after buying an additional 5,523 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.